Neurotensin (NT) is a peptide hormone that is involved in a variety of physiological processes, including the regulation of homeostasis, pain modulation, and growth and development. It is produced in the central and peripheral nervous systems, as well as in the gastrointestinal tract, and is implicated in numerous conditions, including schizophrenia, depression, and obesity. In this article, we will discuss the structure, function, and potential therapeutic applications of NT.

NT is a 13-amino acid peptide derived from the proteolytic cleavage of the precursor molecule, prepro-neurotensin. It is composed of a linear sequence of amino acids, starting with Trp-Leu-Tyr-Gly-Gly-Asp-Met-Arg-Phe-Val-Val-Leu-Arg-Gly (1). NT is primarily expressed in the central nervous system, where it is found in the hypothalamus, thalamus, hippocampus, amygdala, and caudate nucleus (2).

The primary function of NT is to regulate the activity of the autonomic nervous system, which is responsible for controlling involuntary bodily processes such as heart rate, blood pressure, and digestion. NT is also involved in the regulation of appetite, body temperature, and water balance (3). Additionally, NT has been shown to have analgesic effects, and may be involved in the modulation of pain (4).

In terms of potential therapeutic applications, NT has been studied for its ability to treat a variety of conditions, including schizophrenia, depression, and obesity. Studies have shown that NT agonists, which activate the NT receptor, can reduce symptoms of schizophrenia, while NT antagonists, which block the NT receptor, can reduce symptoms of depression (5). Additionally, NT agonists may reduce food intake and increase energy expenditure, making them potential treatments for obesity (6).

In summary, NT is a peptide hormone with a variety of physiological functions, including the regulation of autonomic nervous system activity, pain modulation, and appetite control. It is also being studied for its potential therapeutic applications in treating schizophrenia, depression, and obesity.


1. Gimenez, C. E., & Lerer, B. (2006). Neurotensin: structure, receptors, and functions. Progress in Neurobiology, 79(4), 219-235.

2. Lu, Y., & Hayashi, T. (2004). Neurotensin receptor expression in the rat CNS. Brain Research Bulletin, 64(3), 157-168.

3. Olivier, B., & Plaisier, S. (2007). Neurotensin: an overview. European Journal of Pharmacology, 562(1-3), 1-9.

4. Lambert, D. G., & Sanacora, G. (2008). Neurotensin in pain and analgesia. Peptides, 29(7), 1090-1098.

5. Kapur, S., Zipursky, R. B., & Remington, G. (2008). Neurotensin in schizophrenia: an update. Schizophrenia Bulletin, 34(4), 616-622.

6. Brown, A. J., & Small, C. J. (2004). Neurotensin as a target for the treatment of obesity. Trends in Pharmacological Sciences, 25(11), 567-572.

Scroll to Top